NCT00077649 - A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Combination With COPEGUS (Ribavirin) in Interferon-Naive Patients With Chronic Hepatitis C Infection (CHC). | Biotech Hunter

Enrollment

188

Participants

Timeline

Start Date

January 31, 2004

Primary Completion Date

December 31, 2005

Study Completion Date

December 31, 2005

Conditions

Hepatitis C, Chronic

Interventions

DRUG

ribavirin [Copegus]

600mg po bid for 48 weeks

DRUG

ribavirin [Copegus]

800mg po bid for 48 weeks

DRUG

peginterferon alfa-2a (PEG-IFN alfa-2a) [Pegasys]

180 micrograms sc weekly for 48 weeks

DRUG

peginterferon alfa-2a (PEG-IFN alfa-2a) [Pegasys]

270 micrograms sc weekly for 48 weeks

Trial Locations (25)

11030

Manhasset

15213

Pittsburgh

19104

Philadelphia

23249

Richmond

28677

Statesville

32207

Jacksonville

33414

Wellington

34209

Bradenton

52242

Iowa City

60612

Chicago

63104

St Louis

77030

Houston

84121

Salt Lake City

90822

Long Beach

92105

San Diego

92154

San Diego

96817

Honolulu

92037-1030

La Jolla

06030

Farmington

32610-0214

Gainesville

02111

Boston

27599-7584

Chapel Hill

45267-0595

Cincinnati

22906-0013

Charlottesville

00909

Santurce

All Listed Sponsors

lead

Hoffmann-La Roche

INDUSTRY